Evidence map›Paper›PMID 41829280›Full record

ArticlePolymers2026

Disulfide-Crosslinked Polyurethane-Modified Asphalt: Balancing Fatigue Resistance and Healing Through Dynamic Covalent Networks.

Yemao Zhang, Xijuan Zhao

Abstract read
In one paragraph

Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yemao ZhangNanjing Institute of Technology, Nanjing 211167, China.
Xijuan ZhaoNanjing Institute of Technology, Nanjing 211167, China.

Funding

Transportation Technology Project of Jiangsu Province 2024Z03Transportation Technology Project of Jiangsu Province 2025Z02
6 · The paper itself

Abstract

Thermosetting polyurethane (PU) has recently been introduced as an asphalt modifier to improve the mechanical strength and durability of pavements. However, the permanent crosslinked network of thermosetting PU makes the material difficult to repair once damage accumulates. In contrast, self-healing asphalt technologies rely on either extrinsic healing agents or intrinsic dynamic bonds to restore stiffness and delay cracking. Dynamic disulfide bonds are a promising class of reversible covalent bonds that can rearrange at moderate temperatures and have been widely used to build self-healing polyurethane networks. This study investigates a disulfide-crosslinked polyurethane-modified asphalt binder (DP10) and compares its fatigue and healing performance with base asphalt (BA), thermosetting PU-modified asphalt (P10), and styrene-butadiene-styrene (SBS)-modified asphalts (S3 and S10). A dynamic shear rheometer (DSR) was used to conduct time sweep fatigue tests, linear amplitude sweep (LAS) tests, and fatigue-healing-fatigue protocols. Fourier transform infrared spectroscopy (FTIR) was employed to confirm the formation of polyurethane and disulfide structures. Results show that DP10 significantly increases fatigue life at small to medium strain levels compared with BA and P10 and performs competitively with SBS-modified binders. More importantly, DP10 exhibits a much higher healing index than P10 and maintains strong healing capability over repeated fatigue-healing cycles, approaching the intrinsic healing level of base asphalt. These findings demonstrate that incorporating dynamic disulfide bonds into thermosetting PU networks provides a practical route to binders that combine high strength with recoverability, which is attractive for long-life, self-healing pavement design.

Indexed as

disulfide crosslinkingfatiguemodified asphaltself-healingthermosetting polyurethane

Identifiers

PMID41829280
PMCPMC12987078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.